Compare Starbucks Corp (SBUX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs 10X Genomics Inc — how do they compare? Starbucks Corp trades at $108.48 (market cap $121.59B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: Starbucks Corp is far larger — about 16× 10X Genomics Inc's market cap, and Starbucks Corp pays a 2.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SBUX | TXG | |
|---|---|---|
Market Cap | $121.59B | $7.61B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.37 | $58.57 |
52-Week Low | $78.46 | $11.34 |
Enterprise Value | $140.42B | $7.14B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
